Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gottlieb Shifts From Regulatory To Reimbursement Focus In One Of First Post-Commissioner Appearances

May 13 2019

• By Michael Cipriano

Scott Gottlieb

Related Content

No More Rebates: HHS Proposed Rule Revises Anti-Kickback Safe Harbor

Feb 01 2019

A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?

May 09 2018

Biosimilar Sponsors: We Need To Do A Better Job Educating Physicians And Patients

Sep 18 2018

Biosimilar Leaders Compliment Pfizer For Calling Out Fellow Innovators, But Should FDA Play A Role To Dispel Misinformation?

Sep 20 2018

CAR-T Label Update Could Address Medicare Coverage Challenges, FDA’s Gottlieb Suggests

Nov 14 2018

HHS Message On Value-Based Drug Pricing Complicated But Themes Emerging

Nov 07 2018

Gottlieb Unleashed: Focus on Drug Pricing To Intensify As He Rejoins AEI

Apr 05 2019

Medicare Weighing Higher Add-On Payments For New Drugs, Including CAR-T

Apr 24 2019

No More Rebates: HHS Proposed Rule Revises Anti-Kickback Safe Harbor

Feb 01 2019

Related Companies

Novartis AG

Additional Topics

United States Reimbursement Policy Government Payers Regenerative Medicine BioPharmaceutical Cancer

More from Market Access

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window